Table 1.
The structures and the hedgehog pathway inhibition of target compounds.

| Compd. | R | Gli-luc Reporter IC50 a (μmol/L) | Compd. | R | Gli-luc Reporter IC50 a (μmol/L) |
|---|---|---|---|---|---|
| 5a | ![]() |
28.52 ± 0.02 | 5l | ![]() |
1.83 ± 0.03 |
| 5b | ![]() |
12.47 ± 0.11 | 5m | ![]() |
10.49 ± 0.05 |
| 5c | ![]() |
14.63 ± 0.01 | 5n | ![]() |
5.32 ± 0.13 |
| 5d | ![]() |
15.51 ± 0.03 | 5o | ![]() |
4.28 ± 0.01 |
| 5e | ![]() |
17.59 ± 0.15 | 5p | ![]() |
3.43 ± 0.08 |
| 5f | ![]() |
53.34 ± 0.07 | 5q | ![]() |
1.26 ± 0.03 |
| 5g | ![]() |
60.56 ± 0.04 | 8a | ![]() |
6.88 ± 0.13 |
| 5h | ![]() |
7.85 ± 0.01 | 8b | ![]() |
12.7 ± 0.16 |
| 5i | ![]() |
16.32 ± 0.05 | 8c | ![]() |
8.62 ± 0.09 |
| 5j | ![]() |
4.74 ± 0.02 | MRT10 b | 2.15 | |
| 5k | ![]() |
16.61 ± 0.12 | Vismodegib b | 0.025 |
a The values are an average of triplicate separate determinations. b Used as a positive control.



















